Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fimasartan Effectiveness and Safety in Mexican Patients with Essential Hypertension
NCT02466490Phase 3Completed
- Sponsor
- Stendhal Pharma
- Start
- Apr 2013
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fimasartan in essential hypertension (4 arms), sponsored by Stendhal Pharma. Primary endpoint: Blood Pressure Change From Baseline at 8 weeks. Started Apr 2013; status: completed.
02
Drugs
fimasartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT02466490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02466490.